Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHA pretreatment plus ALA photodynamic therapy for facial premalignant field cancerization
ACTRN12609000025235Phase 3Not yet recruiting
- Sponsor
- Allmedic
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of 5-aminolevulinic acid in actinic keratosis (AK), cutaneous malignancy and field cancerization (FC), sponsored by Allmedic. Primary endpoint: Incidence of subsequent invasive facial skin cancers. Planned start Jan 2009; status: not yet recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)cutaneous malignancyfield cancerization (FC)
Beyond the preview
Go deeper on ACTRN12609000025235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000025235.